A surprising segment of the stock market will rally the most on a COVID-19 vaccine, Goldman Sachs says

A surprising segment of the stock market will rally the most on a COVID-19 vaccine, Goldman Sachs says

Traders work on the floor of the New York Stock Exchange shortly after the opening bell in New York, U.S., March 17, 2020.

Lucas Jackson/Reuters

Expect value stocks, not cyclical stocks, to rally the most from a COVID-19 vaccine, Goldman Sachs said in a note on Friday.As chances have increased that a successful COVID-19 vaccine will be developed, value stocks have rallied the most of any other group of stocks, the note highlighted.But while value stocks will likely stage a strong rally on a COVID-19 vaccine development, growth stocks should remain the favored pick for investors with a long-term investment horizon, Goldman said.Visit the Business Insider homepage for more stories.

As the world awaits a successful COVID-19 vaccine, investors are anticipating which stocks to buy to benefit off of the potential development.

And